These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 2346317)

  • 1. Augmentation of cytotoxicity of lymphokine activated killer cells on ovarian tumor cells by various biological response modifiers.
    Nio Y; Zighelboim J; Berek JS; Bonavida B
    Anticancer Res; 1990; 10(2A):441-6. PubMed ID: 2346317
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sensitivity of ovarian tumor cells to effector cells generated by various biological response modifiers.
    Nio Y; Zighelboim J; Berek JS; Bonavida B
    Nat Immun Cell Growth Regul; 1990; 9(4):283-96. PubMed ID: 2215516
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lymphokine-activated effector cells: modulation of activity by cytokines.
    Mehta S; Flanagan P; Blackinton D; Wanebo H
    Lymphokine Cytokine Res; 1992 Apr; 11(2):73-7. PubMed ID: 1581419
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Effect of malignant ascitic fluids and OK-432 on the induction of LAK activity in peripheral blood mononuclear cells of gynecological cancer patients].
    Kanaoka Y; Umesaki N
    Nihon Sanka Fujinka Gakkai Zasshi; 1991 Jun; 43(6):611-8. PubMed ID: 1856521
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induction by OK-432 of lymphokine activated killer precursor cells in hepatocellular carcinoma.
    Aramaki M; Kim YI; Shimoda K; Nakashima K; Okada K; Kobayashi M
    Hepatogastroenterology; 1994 Aug; 41(4):363-6. PubMed ID: 7959572
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytotoxicity against autologous, allogeneic, and xenogeneic tumor targets by human recombinant interleukin-2-activated lymphocytes from healthy dogs and dogs with lung tumors.
    Mitchell DH; Withrow SJ; Johnston MR; Kruse CA
    Am J Vet Res; 1991 Jul; 52(7):1132-6. PubMed ID: 1892269
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of various cytokines on the induction of lymphokine-activated killer cells.
    Bergmann L; Weidmann E; Bungert B; Hechler P; Mitrou PS
    Nat Immun Cell Growth Regul; 1990; 9(4):265-73. PubMed ID: 2120581
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interleukin-12 synergizes with interleukin-2 to generate lymphokine-activated killer activity in peripheral blood mononuclear cells cultured in ovarian cancer ascitic fluid.
    Barton DP; Blanchard DK; Duan C; Roberts WS; Cavanagh D; DeCesare S; Djeu JY
    J Soc Gynecol Investig; 1995; 2(6):762-71. PubMed ID: 9420887
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [A basic study of combination cancer immunotherapy with OK-432 and rIL-2--induction of lymphokine-activated killer (LAK) precursor cells in murine spleen by intravenous administration of OK-432].
    Shimoda K; Saito T; Kobayashi M
    Nihon Gan Chiryo Gakkai Shi; 1988 Jul; 23(7):1566-73. PubMed ID: 3263451
    [No Abstract]   [Full Text] [Related]  

  • 10. Clinical and biological effects of intraperitoneal injections of recombinant interferon-gamma and recombinant interleukin 2 with or without tumor-infiltrating lymphocytes in patients with ovarian or peritoneal carcinoma.
    Freedman RS; Kudelka AP; Kavanagh JJ; Verschraegen C; Edwards CL; Nash M; Levy L; Atkinson EN; Zhang HZ; Melichar B; Patenia R; Templin S; Scott W; Platsoucas CD
    Clin Cancer Res; 2000 Jun; 6(6):2268-78. PubMed ID: 10873077
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytolysis of malignant glioma cells by lymphokine-activated killer cells combined with anti-CD3/antiglioma bifunctional antibody and tumor necrosis factor-alpha.
    Yoshida J; Takaoka T; Mizuno M; Momota H; Okada H
    J Surg Oncol; 1996 Jul; 62(3):177-82. PubMed ID: 8667624
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effective in vivo induction of lymphokine-activated killer (LAK) cells by pretreatment with a streptococcal preparation, OK-432.
    Shimoda K; Saito T; Kobayashi M; Nomoto K
    Biotherapy; 1992; 5(1):63-9. PubMed ID: 1389903
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor-specific lysis of human renal cell carcinomas by tumor-infiltrating lymphocytes: modulation of recognition through retroviral transduction of tumor cells with interleukin 2 complementary DNA and exogenous alpha interferon treatment.
    Schendel DJ; Gansbacher B
    Cancer Res; 1993 Sep; 53(17):4020-5. PubMed ID: 8358731
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of TNF-alpha and IFN-alpha on the proliferation and cytotoxicity of lymphokine-activated killer cells in patients with bladder cancer.
    Wang Z; Cheng Y; Zheng R; Qin D; Liu G
    Chin Med J (Engl); 1997 Mar; 110(3):180-3. PubMed ID: 9594335
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: direct correlation between reduction of established metastases and cytolytic activity of lymphokine-activated killer cells.
    Mulé JJ; Yang J; Shu S; Rosenberg SA
    J Immunol; 1986 May; 136(10):3899-909. PubMed ID: 2871106
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Preparation of NK-enriched LAK cells--their potential cytotoxic and ADCC activities].
    Kobayashi Y; Sudo T; Matsushita N; Nakao M; Tanaka Y; Shimizu K; Tanigawa K; Aruga A
    Gan To Kagaku Ryoho; 2003 Oct; 30(11):1776-9. PubMed ID: 14619517
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Endogenous production of tumor necrosis factor in normal mice and human cancer patients by interferons and other cytokines combined with biological response modifiers of bacterial origin.
    Satoh M; Inagawa H; Shimada Y; Soma G; Oshima H; Mizuno D
    J Biol Response Mod; 1987 Oct; 6(5):512-24. PubMed ID: 2445926
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transforming growth factor-beta 1 (TGF-beta 1) and recombinant human tumor necrosis factor-alpha reciprocally regulate the generation of lymphokine-activated killer cell activity. Comparison between natural porcine platelet-derived TGF-beta 1 and TGF-beta 2, and recombinant human TGF-beta 1.
    Espevik T; Figari IS; Ranges GE; Palladino MA
    J Immunol; 1988 Apr; 140(7):2312-6. PubMed ID: 3280680
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Non-cytotoxic and sublethal paclitaxel treatment potentiates the sensitivity of cultured ovarian tumor SKOV-3 cells to lysis by lymphokine-activated killer cells.
    Law KS; Chen HC; Liao SK
    Anticancer Res; 2007; 27(2):841-50. PubMed ID: 17465210
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Circulating cytokines in patients with metastatic cancer treated with recombinant interleukin 2 and lymphokine-activated killer cells.
    Gemlo BT; Palladino MA; Jaffe HS; Espevik TP; Rayner AA
    Cancer Res; 1988 Oct; 48(20):5864-7. PubMed ID: 3139285
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.